Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 4, 2016, Pages 784-793

  Siudut, J ^a   Grela, M ^b   Wypasek, E ^a,b   Plens, K ^c   Undas, A ^a,b  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Krakow Cardiovascular Research Institute   (Poland)

Author keywords

Fibrin; Fibrinogen; Fibrinolysis; Postthrombotic syndrome; Thrombosis

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; D DIMER; FIBRIN; FIBRINOGEN; FIBRINOLYTIC FACTOR; GLUCOSE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; BODY MASS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; D DIMER BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME ACTIVITY; EUGLOBULIN LYSIS TEST; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HIGH RISK POPULATION; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PLASMA FIBRIN CLOT LYSABILITY; PLASMA FIBRIN CLOT PERMEABILITY; POSTTHROMBOSIS SYNDROME; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; ADOLESCENT; BLOOD; BLOOD CLOTTING; CHEMISTRY; FIBRINOLYSIS; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PERMEABILITY; RISK; VEIN; VEIN THROMBOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION; COHORT STUDIES; FEMALE; FIBRIN; FIBRIN CLOT LYSIS TIME; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERMEABILITY; POSTTHROMBOTIC SYNDROME; RISK; THROMBIN; VEINS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84962692574     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13264     Document Type: Article

References (41)

1. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
2. Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.
3. Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, Gupta DK, Prandoni P, Vedantham S, Walsh ME, Weitz JI; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2014; 130: 1636-61.
4. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, Bernardi E, Girolami B, Simioni P, Girolami A. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82: 423-8.
5. Bouman AC, Smits JJM, Ten Cate H, Ten Cate-Hoek AJ. Markers of coagulation, fibrinolysis and inflammation in relation to postthrombotic syndrome. J Thromb Haemost 2012; 10: 1532-8.
6. Schulman S, Lindmarker P, Holmström M, Lärfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4: 734-42.
7. Galanaud JP, Holcroft CA, Rodger MA, Kovacs MJ, Betancourt MT, Wells PS, Anderson DR, Chagnon I, Le Gal G, Solymoss S, Crowther MA, Perrier A, White RH, Vickars LM, Ramsay T, Kahn SR. Predictors of postthrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. J Thromb Haemost 2013; 11: 474-80.
8. Ageno W, Piantanida E, Dentali F, Steidl L, Mera V, Squizzato A, Marchesi C, Venco A. Body mass index is associated with the development of the postthrombotic syndrome. Thromb Haemost 2003; 89: 305-9.
9. Kahn SR, Kearon C, Julian JA, Mackinnon B, Kovacs MJ, Wells P, Crowther MA, Anderson DR, van Nguyen P, Demers C, Solymoss S, Kassis J, Geerts W, Rodger M, Hambleton J, Ginsberg JS; Extended Low-intensity Anticoagulation for Thrombo-embolism (ELATE) Investigators. Predictors of the postthrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost 2005; 3: 718-23.
10. Undas A, Ariëns RAS. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
11. Undas A. Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost 2014; 112: 32-42.
12. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-73.
13. Rooth E, Wallen NH, Blombäck M, He S. Decreased fibrin clot network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke. Thromb Res 2011; 127: 51-6.
14. Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydłowska A, Skubiszak A, Ciepłuch K, Tracz W. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-8.
15. Undas A, Cieśla-Dul M, Drazkiewicz T, Sadowski J. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform. Thromb Res 2012; 130: e184-7.
16. Rabinovich A, Cohen JM, Cushman M, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Lazo-Langner A, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, et al. Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of postthrombotic syndrome. J Thromb Haemost 2015; 13: 398-408.
17. Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C. Definition of postthrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009; 7: 879-83.
18. Pankiw-Bembenek O, Zalewski J, Goralczyk T, Undas A. A history of early stent thrombosis is associated with prolonged clot lysis time. Thromb Haemost 2012; 107: 513-20.
19. Mills JD, Ariëns RAS, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-42.
20. Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-5.
21. Undas A, Wypasek E, Kapelak B, Sadowski J. Shorter preoperative fibrin clot lysis time predisposes to higher chest tube drainage in patients undergoing elective coronary artery bypass grafting surgery. Blood Coagul Fibrinolysis 2010; 21: 380-1.
22. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-36.
23. Celińska-Lowenhoff M, Iwaniec T, Padjas A, Musiał J, Undas A. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation. Thromb Haemost 2014; 112: 287-96.
24. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-21.
25. Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res 2010; 125: 357-61.
26. Hosmer DW Jr, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons, 1989.
27. Eichinger S, Schönauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-6.
28. Foley JH, Kim PY, Mutch NJ, Gils A. Insights into thrombin activatable fibrinolysis inhibitor function and regulation. J Thromb Haemost 2013; 11(Suppl. 1): 306-15.
29. Meltzer ME, Bol L, Rosendaal FR, Lisman T, Cannegieter SC. Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow-up study. J Thromb Haemost 2010; 8: 605-7.
30. Traby L, Kollars M, Eischer L, Eichinger S, Kyrle PA. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS ONE 2012; 7: e51447.
31. Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
32. Rabinovich A, Kahn SR. How to predict and diagnose postthrombotic syndrome. Pol Arch Med Wewn 2014; 124: 410-6.
33. Rabinovich A, Cohen JM, Kahn SR. The predictive value of markers of fibrinolysis and endothelial dysfunction in the post thrombotic syndrome. A Systematic Review. Thromb Haemost 2014; 111: 1031-40.
34. Tick LW, Kramer MHH, Rosendaal FR, Faber WR, Doggen CJM. Risk factors for postthrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost 2008; 6: 2075-81.
35. Baldwin MJ, Moore HM, Rudarakanchana N, Gohel M, Davies AH. Post-thrombotic syndrome: a clinical review. J Thromb Haemost 2013; 11: 795-805.
36. Dunn EJ, Ariëns RA, Grant PJ. The influence of type 2 diabetes on clot structure and function. Diabetologia 2005; 48: 1198-206.
37. Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, Dunn EJ, Anwar MM, Rabbani N, Thornalley PJ, Philippou H, Grant PJ. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood 2013; 122: 134-42.
38. Gronostaj K, Richter P, Nowak W, Undas A. Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation. Thromb Res 2013; 131: 262-7.
39. Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, Sheikh T. Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 2003; 42: 1043-57.
40. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Houweling AH, Ducruet T, Holcroft C, Johri M, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, et al. Ginsberg JS; SOX trial investigators. Compression stockings to prevent postthrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383: 880-8.
41. Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood 2013; 121: 1712-9.